Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 4/20 | 0.59 |
| ▸ | VDR | P11473 | 4/20 | 0.59 |
| ▸ | CASP7 | P55210 | 3/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.59 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.59 |
| ▸ | TP53 | P04637 | 2/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.59 |
| ▸ | BLM | P54132 | 2/20 | 0.59 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.59 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | USP2 | O75604 | 2/20 | 0.59 |
| ▸ | MDM4 | O15151 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.59 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10226261 | 0.92 | GPBAR1 (0.61) | GPBAR1VDRCASP7HSD17B10TDP1 | |
| SCHEMBL10226251 | 0.92 | GPBAR1 (0.61) | GPBAR1VDRCASP7HSD17B10TDP1 | |
| SCHEMBL22855456 | 0.90 | VDR (0.70) | GPBAR1VDRCASP7HSD17B10TDP1 | |
| SCHEMBL17817283 | 0.88 | CDC25A (0.65) | GPBAR1VDRCASP7HSD17B10TDP1 | |
| SCHEMBL18629123 | 0.87 | USP2 (0.54) | GPBAR1VDRCASP7HSD17B10TDP1 | |
| SCHEMBL14978143 | 0.87 | USP2 (0.54) | GPBAR1VDRCASP7HSD17B10TDP1 | |
| SCHEMBL18628061 | 0.87 | USP2 (0.52) | GPBAR1VDRCASP7HSD17B10TDP1 | |
| SCHEMBL18629132 | 0.87 | USP2 (0.54) | GPBAR1VDRCASP7HSD17B10TDP1 | |
| SCHEMBL24193196 | 0.86 | USP2 (0.53) | GPBAR1VDRCASP7HSD17B10TDP1 | |
| SCHEMBL21101187 | 0.86 | USP2 (0.53) | GPBAR1VDRCASP7HSD17B10TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120277448-A1 | PREPARATION METHOD FOR 3BETA-ARACHIDYLAMIDO-7ALPHA, 12ALPHA, 5BETA-CHOLAN-24-CARBOXYLIC ACID | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2012-11-01 | — | — | US | claimed |
| US-20120277448-A1 | PREPARATION METHOD FOR 3BETA-ARACHIDYLAMIDO-7ALPHA, 12ALPHA, 5BETA-CHOLAN-24-CARBOXYLIC ACID | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2012-11-01 | — | — | US | disclosed |
| US-20120277448-A1 | PREPARATION METHOD FOR 3BETA-ARACHIDYLAMIDO-7ALPHA, 12ALPHA, 5BETA-CHOLAN-24-CARBOXYLIC ACID | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2012-11-01 | — | — | US | disclosed |
| WO-2011079672-A1 | PREPARATION METHOD FOR 3-Β-ARACHIDYLAMIDO-7Α,12Α,5Β-CHOLAN-24-CARBOXYLIC ACID | 上海特化医药科技有限公司 (CN) | 2011-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277448-A1 | PREPARATION METHOD FOR 3BETA-ARACHIDYLAMIDO-7ALPHA, 12ALPHA, 5BETA-CHOLAN-24-CARBOXYLIC ACID | CYP46A1, CYP7A1, CYP7B1 | GPBAR1 131/4885VDR 1764/4885CASP7 375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.